← Back to Clinical Trials
Recruiting NCT06588647

NCT06588647 Improving Participation After Stroke Self-Management-Rehabilitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06588647
Status Recruiting
Phase
Sponsor University of Missouri-Columbia
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-12-16
Primary Completion 2029-12-15

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Improving Participation after Stroke Self-Management Program (IPASS)Chronic Disease Self-Management Program (CDSMP)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-12-16 with a primary completion date of 2029-12-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall goal of this proposed study is to evaluate the efficacy of a small-group, stroke-specific, self-management program delivered via telehealth to improve self-efficacy, activity performance, and quality of life in individuals with sub-acute stroke.

Eligibility Criteria

Inclusion Criteria: * less than 6 months post-stroke * age 45-85 years * completed inpatient rehabilitation services (if recommended) * living in the community with or without caregiver support (i.e., not living in a skilled nursing facility) * ability to read, write, and speak English * diagnosis of mild or moderate stroke (National Institutes of Health stroke score \<16) * able to use videoconferencing independently or with caregiver support Exclusion Criteria: * severe depressive symptoms as indicated by a score ≥21 on the Patient Health Questionnaire * dementia symptoms as indicated by a score of \<23 on the Montreal Cognitive Assessment * additional neurological diagnoses (e.g., brain malignancy, previous severe stroke) * (4) moderate or severe aphasia as indicated by a National Institutes of Health Stroke Scale aphasia score of ≥ 2 * inability to provide informed consent * any other condition not otherwise specified that the PI determines would render participation in this study as unsafe for the participant

Contact & Investigator

Central Contact

Anna E Boone, PhD, OTR/L

✉ booneae@umsystem.edu

📞 5738827023

Principal Investigator

Anna E Boone, PhD, OTR/L

PRINCIPAL INVESTIGATOR

University of Missouri Occupational Therapy

Frequently Asked Questions

Who can join the NCT06588647 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, up to 85 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06588647 currently recruiting?

Yes, NCT06588647 is actively recruiting participants. Contact the research team at booneae@umsystem.edu for enrollment information.

Where is the NCT06588647 trial being conducted?

This trial is being conducted at Columbia, United States.

Who is sponsoring the NCT06588647 clinical trial?

NCT06588647 is sponsored by University of Missouri-Columbia. The principal investigator is Anna E Boone, PhD, OTR/L at University of Missouri Occupational Therapy. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology